Hepalink(SZ:002399)2025-01-24 09:45Financial Performance - The company expects a net profit attributable to shareholders of between 58.9 million and 71.1 million yuan for 2024, a significant recovery from a loss of 78.3 million yuan in the previous year[2] - The net profit after deducting non-recurring gains and losses is projected to be between 21.4 million and 31.2 million yuan, compared to a loss of 77.98 million yuan in the same period last year[2] - Basic earnings per share are anticipated to be between 0.4014 yuan and 0.4846 yuan, recovering from a loss of 0.5338 yuan per share in the previous year[2] Market Conditions - The heparin industry chain's operating environment has improved, with a gradual recovery in market demand, leading to growth in sales of the main product, enoxaparin sodium, across various markets[4] - The global demand for heparin API has improved year-on-year, with an increase in export volume from China, although the average export price has significantly decreased due to lower raw material prices[4] Business Development - The company's CDMO business continues to recover, strengthening strategic partnerships with existing clients and exploring new customer groups to enhance revenue and profitability[5] - The company has optimized its external investment strategy, achieving significant progress and good investment returns during the reporting period[5]